ArticleNucleic acids research2026
Discovering proteo-transcriptomic networks via biologically informed heterogeneous graph learning.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Cancers are shaped by genetic interactions across multiple omics layers. Despite substantial progress made at the genomic and transcriptomic levels, the detailed interplay among mRNA, proteins, and protein modifications as well as the corresponding actionable targets remained poorly explored. Here, we developed bioGraph, a biologically informed graph learning method designed to systematically identify proteo-transcriptomic networks from transcriptomic, proteomic, and phosphoproteomic data. By incorporating genetic interaction priors into a unique three-layered heterogeneous graph, bioGraph revealed functional intra-omic, inter-omic, and cross-omic regulatory networks with prognostic relevance, including previously overlooked interactions modulating cancer hallmarks. We introduced a multi-omic gene set variation analysis score to quantify the network activity. We applied bioGraph to pan-cancer datasets and identified trans-omic regulatory hub genes undetectable by conventional methods. MAP4 emerged as a marker associated with tumor growth and malignant behaviors, validated via external datasets and tumor cell line assays, demonstrating its therapeutic potential. Our findings establish bioGraph as a new tool for identifying proteo-transcriptomic networks and gene targets with rapidly expanding underutilized multi-omic resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.